Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evenamide - Newron Pharmaceuticals

Drug Profile

Evenamide - Newron Pharmaceuticals

Alternative Names: NW-3509; NW-3509A

Latest Information Update: 25 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Newron Pharmaceuticals
  • Class Antidepressants; Antiepileptic drugs; Antimanics; Antipsychotics; Non-opioid analgesics; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Nav1.3 voltage-gated sodium channel inhibitors; Nav1.7 voltage-gated sodium channel inhibitors; Nav1.8 voltage-gated sodium channel inhibitors; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Schizophrenia

Most Recent Events

  • 13 Sep 2018 Newron plans two pivotal phase III trials in Schizophrenia in the first half of 2019 (700288917; 700291218)
  • 02 Apr 2018 Phase-I clinical trials in Schizophrenia (In volunteers) in United Kingdom (PO) (NCT03446274)
  • 26 Feb 2018 Newron Pharmaceuticals plans a phase I trial for Schizophrenia (In volunteers) in March 2018 (PO) (NCT03446274)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top